Skip to main content

Table 3 Components of the Clinical Impression of Change in Severity© (CI-CS) Assessment

From: A master protocol to investigate a novel therapy acetyl-l-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia

TASK

TIMEPOINT

RESPONSIBLE PERSON(S)

Determine CI-CS Primary Anchor Test (8MWT or 9HPT-D)

Visit 1

Principal Investigator

Anchor Tests Video Recordings

Visit 2, 3, 4, 5, 6, 7, 8, 9, 10, Early Termination (as applicable)

Qualified Video-Recorder (Study Team Member)

CI-S & CI-CS Assessment Anchor Tests

Following Last Visit (Parent Study: Visit 6; Extension Phase: Visit 10)

Blinded Independent Raters